Novel and Practical Industrial Process Scale-Up of 5-Bromo-2-chloro-4-(methoxycarbonyl)benzoic acid, a Key Intermediate in the Manufacturing of Therapeutic SGLT2 Inhibitors

Abstract

5-Bromo-2-chloro-4-(methoxycarbonyl)benzoic acid (1) is a key intermediate for the synthesis of a family of promising SGLT2 inhibitors currently in preclinical and phase I studies for diabetes therapy. In this investigation, cheap, easily available dimethyl terephthalate was used as the raw starting material, and compound 1 was prepared effectively in six steps, including nitration, hydrolysis, hydrogenation, esterification, bromination, and diazotization. The preparation was run successfully on approximately 70 kg/batch with the total yield of 24%. This practical process was demonstrated to be scalable with a great yield and significant cost reduction.

Keywords

5-bromo-2-chloro-4-(methoxycarbonyl)benzoic acid - SGLT2 inhibitors - practical process - scale up

Publikationsverlauf

Eingereicht: 28. Februar 2022

Angenommen: 16. Juni 2022

Artikel online veröffentlicht:
22. August 2022

• References

• 1 Manoj A, Das S, Kunnath Ramachandran A, Alex AT, Joseph A. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. Future Med Chem 2020; 12 (21) 1961-1990
• 2 Xu B, Lv B, Feng Y. et al. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem Lett 2009; 19 (19) 5632-5635
• 3 Lv B, Xu B, Feng Y. et al. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem Lett 2009; 19 (24) 6877-6881
• 4 Prous JR, Serradell N, Munoz R. et al. Preparation of pyrano[3,2-c]benzopyran-6(2h)-one derivatives as SGLT2 antidiabetic agents. WO Patent 2013045495 A1. April 2013
• 5 Liu H, Li J, Wang J. Process for preparation of C,O-spiro aryl glycoside compounds and use thereof. WO Patent 2016206604 A1. December, 2016
• 6 Kroh C, Lang IU, Rose H. et al. Use of sodium-dependent glucose transporter SGLT2 inhibitors for the prevention and/or treatment of cardiac diseases in felines. WO Patent 2021165177 A1. August, 2021
• 7 Chen YW, Feng Y, Xu BH. et al. Preparation of benzylic glycoside derivatives and their inhibitory effect on sodium-dependent glucose co-transporter SGLT. US Patent 20080242596 A1. October, 2008
• 8 Liu YH, Fu TM, Ou CY. et al. Improved preparation of (1S,3′R,4‘S,5′S,6’R)-5-chloro-6-[(4-ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)-spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol. Chin Chem Lett 2013; 24 (02) 131-133
• 9 Lee SH, Kim MJ, Lee SH, Kim J, Park HJ, Lee J. Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors. Eur J Med Chem 2011; 46 (07) 2662-2675
• 10 Qin ZW, Liu C, Shi YL. et al. Method for preparing 2-amino-4-methanesulfonamide methylbenzoate. CN Patent 103524386 A. January, 2014
• 11 Li Z, Zhang X, Zhang X. et al. ¹⁸F-Labeled benzyldiamine derivatives as novel flexible probes for positron emission tomography of cerebral β-amyloid plaques. J Med Chem 2016; 59 (23) 10577-10585
• 12 Skibo EB, Gilchrist JH. Synthesis and electrochemistry of pyrimidoquinazoline-5,10-diones. Design of hydrolytically stable high potential quinones and new reductive alkylation systems. J Org Chem 1988; 53 (18) 4209-4218
• 13 Ursuegui S, Yougnia R, Moutin S. et al. A biotin-conjugated pyridine-based isatoic anhydride, a selective room temperature RNA-acylating agent for the nucleic acid separation. Org Biomol Chem 2015; 13 (12) 3625-3632
• 14 Bauer E, Gerlach K, Pfau R. et al. Novel substituted nitrogen-containing heterobicycles and use thereof as factor Xa inhibitors. CA Patent 2511349 A1. July, 2004
• 15 Kim M, Boissonnault JA, Dau PV, Cohen SM. Metal-organic framework regioisomers based on bifunctional ligands. Angew Chem Int Ed Engl 2011; 50 (51) 12193-12196
• 16 Chen YW, Feng Y, Xu BH. et al. Glucose transport inhibitors and methods of use. US Patent 2007275907 A1. November, 2007